Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
See you in dollar land real soon.
I'm in boys...some big things planned for this diamond.
Huge bids up here now !!!
Yep....and it just blew....
.15 here on the Canadian side...
Market telling us the lithium results are stellar...
Great day and strong close today guys and girls.
Definitely something brewing for this junior contender in the race for space.
Been in and buying since the initial debut up north.
Where in the heck can you get a rocket company for this kind of share price ?!?
KA BOOM
Upcoming February NAV should be about $3.59 cdn imho.
EDISON, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- StrikeForce Technologies, Inc. (OTC PINK: SFOR), as of Friday January 29th, 2021, “StrikeForce has completed its Reg A Tier II funding round, and in doing so we only needed to sell 465,000,000 common shares for a total outstanding of 757,000,000 common shares as against a total outstanding of 800,000,000 common shares originally considered and planned for. That’s 43,000,000 less common shares in the market, the Offering Circular only required 465,000,000 common shares being sold to complete the offering. This is a correction statement for clarity,” says Mr. Kay, CEO of StrikeForce.
“In addition to the correction fact above, adding further clarity, I also stated in a prior release, 'as paying off the variable convertible debt of about $900,000 plus interest and fees,' is inaccurate. Even though about $900,000 was about the amount of debt retired, the variable conversion notes weren’t paid off, they were either converted or forgiven (as disclosed in the the Current Report on Form 8-K as filed with the SEC), even though the amount was correct,” says Mark Kay, CEO of StrikeForce. “Thanks for believing in us and investing in the Reg A and for those of you that partook in it. I do apologize for these points of clarity,” says Kay.
Here we go boys and girls....
Don't think there's a market for this ?
Zoom ?
China-Based Executive at U.S. Telecommunications Company Charged with Disrupting Video Meetings Commemorating Tiananmen Square Massacre -
https://t.co/xjtbH8Nogl
https://twitter.com/BenKTallmadge/status/1339997841775755264?s=19
Appreciate the post ! I'm not a skilled tactician, certainly years of experience though under my belt. A tremendous case you've put forward here. Again appreciate the effort and if we had more forum posters like you on these board and less of the idiots, we'd all be better off.
Onward and upward...
GAP UP in the morning ...
VERY HUGE....
What with the recent hack of a multitude of government departments....
Id have to say encryption and end to end security....aint a bad thing...
How long till the feds sign up...
This has kaboom written all over it...
A great video....
Not sure some of the village idiots on these boards can comprehend the enormity of this story though....
Great post !
Interesting post from CEO.ca...on the HRE board...
Ive heard similar re: buyout from a geologist friend of mine who works as a rare earths analyst for a brokerage in London, England...
@Hoping4a10bagger I'm betting we get bought out by a private company or the Russian Government. the AGM in Jan 2019 the directors brought up Uranium One they had deal with the Russians then the Russians bought them out.we are on a smaller scale. i didnt attend the agm the above info was posted on another website. there have been no insider transactions since sept 6 and insiders are prohibited from trading in their securities when they are in receipt of non public info. theres been over 2 months without any insider transaction basically. THEY MUST have non public info. or else they would have sold their shares along everyone else after The INCIDENT on aug 21. Stans has a binding mou to buy the Zavitinsky lithium stockpile in russia. We applied for the IIPRs for lithium processing technology to export it. there may be other reasons that i dont remember right now. if we do get bought out by anyone im pretty sure the buyout price per share should be over $0.05 because all the warrants from the PP and all the options are priced at $0.05
Interesting, I wonder who did all the buying the last couple of days then ?
Seems to be a rumour floating around about a buy out.
Potential lotto ticket here, big volume and buying out of nowhere.
Somethings up.....
Rumor of something coming...
All good...I made a few bucks...5 would have been awesome but whatever....its the business we're in...
Lol...not looking so...
In for a trade at 2.60.
Short squeeze coming....
MGNA is under short restriction...
No more to borrow and lots to cover...
https://www.nasdaqtrader.com/trader.aspx?id=shortsalecircuitbreaker
Going to it now...thanks for the heads up..thinking of getting some here...trying to establish a time frame for a move to $1/$2 for example as well...
Thanks and no problem will do so..just came upon a few minutes a go...
All time high in this was $375 ????....in 2016...
Something large must be going on !!! Record volume and price increase here ...
www.cannabisfn.com/pivot-pharma-wraps-successful-2017/
The North American cannabis industry reached $6.7 billion in 2016, according to ArcView Research, which represented a healthy 30% growth rate over the prior year. Over the next three years, the analyst firm expects the industry to grow at a 25% compound annual growth rate to reach $20.2 billion in sales. One company, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF), successfully completed an about-face in 2017 to focus exclusively on the explosive sector. In this article, we will review the company’s achievements and how its business model aligns with trends in the industry.
New Focus on Cannabis
Pivot Pharmaceuticals first announcement related to cannabis came on September 12, 2017. The company acquired worldwide rights and a patent for the proprietary BiPhasix™ Transdermal Drug Delivery technology, for the development of cannabis-related products. The technology has been shown to significantly enhance the bioavailability of drugs by transporting them effectively through the skin, and the drugs delivered in this manner can target peripheral areas of the body to deliver a payload through the skin without damaging the organ from repeated application.
The acquisition was intended to address cannabinoid delivery which is an overarching problem throughout the industry. Smoking is not necessarily a preferred delivery mechanism due mostly to side effects and health concerns, and ingestion is ineffective due to metabolic effects of the liver as well as inherent problems with the absorption of cannabinoids due to insolubility in water. So Pivot Pharma’s first move was to acquire a proven technology and focus it on cannabis. But the company was by no means done.
Pivot announced two weeks later the acquisition of worldwide rights to Solmic Research GmbH’s Solmic Solubilisation Technology. This is an oral delivery technology that makes cannabinoids water-soluble and protects them from degradation due to stomach acids and enzymes. The technology masks unpleasant odour and taste and improves stability of the mixture. Pivot is advancing several Natural Health Products as a result of this technology, including products intended for opioid addicts and cancer patients.
A few weeks later, in early November, Pivot entered into a binding agreement to acquire a third delivery technology, Thrudermic’s Transdermal Nanotechnology. This new technology allows Pivot to control and prolong the release of cannabinoid actives while maintaining high concentrations of the drug throughout the application period. Unlike BiPhasix™, the Thrudermic technology allows for more sophisticated systemic exposure from fast uptake to slow release.
Taken together, the three delivery technologies provide a wide array of options for development and commercialization of cannabinoid-based nutraceuticals and medicines. While many companies are focused on the production and sale of cannabis flower products, there is an increasing demand for more specific and refined products utilizing extracts from the cannabis plant.
Positioning for a Big Year
With some innovative delivery technologies in place, Pivot Pharma entered into another binding agreement, this time for the acquisition of ERS Holdings, LLC. ERS has a patented technology called Ready to Infuse Cannabis (RTIC) that changes cannabis oil extracts into a tasteless powder suitable for infusion into food and beverage products. Cannabis oils suffer from the above-mentioned bioavailability issues, but also have a notorious taste problem. The RTIC technology solves both issues, and opens up a whole world of consumer product possibilities for Pivot Pharmaceuticals.
In a final move before the end of the year, the company entered into a binding agreement to establish a California-based business to accelerate the commercialization of the newly-acquired RTIC powders. With California poised to fully legalize cannabis on Jan. 1, 2018, thereby becoming the world’s largest legal cannabis market, Pivot is looking to quickly capitalize on the innovative technology.
Looking Ahead
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) just recently started trading on the Canadian Securities Exchange, opening up the company’s stock to a whole new market of cannabis-savvy investors. Additionally, the company announced a 45-day standstill agreement that will end on February 6, 2018. In the interim, Pivot hopes to finalize a partnership with a “…best-in-class partner to monetize our patented technologies…” The agreement means that Pivot will not enter into or negotiate any other partnerships within the 45-day period. Read into this what you will, but with Canada and California both legalizing adult use of cannabis in 2018, the year ahead should be full of interesting developments for Pivot Pharmaceuticals.
For more information, visit the company’s website at www.pivotpharma.com.
Pivot signs standstill deal with potential partner
2017-12-27 06:27 ET - News Release
Mr. Patrick Frankham reports
PIVOT ENTERS INTO STANDSTILL AGREEMENT
Pivot Pharmaceuticals Inc. has entered into a 45-day standstill period with a Toronto Stock Exchange-listed company in order to explore a business opportunity of mutual interest and benefit, that may result in a co-research and development program, a product launch and/or commercialization agreement, or some other form of potential partnership.
The standstill period will end on Feb. 6, 2018. During this time Pivot will not, directly or indirectly, conduct or enter negotiations or engage in any other discussions or communications with any third party regarding a potential transaction, any sale of all or substantially all of the assets of Pivot, or any merger, amalgamation, plan of arrangement or other business combination involving Pivot.
Dr. Patrick Frankham, Pivot's chief executive officer, stated that: "The Pivot team has been working tirelessly to secure a best-in-class partner to monetize our patented technologies and to bring our impressive pipeline of products to market in preparation for the legalization of cannabis in Canada and areas of the U.S. and European Union. During the past few months we have garnered interest from established companies in the nutraceutical and cannabis industries. Pivot's management is committed to exploring all potential avenues to consummate a transaction with the company that we have a standstill agreement with as they share our vision of developing, manufacturing and commercializing premium science-based cannabis products to serve the health needs of consumers. On behalf of the board of directors of Pivot, I would like thank our shareholders for their continued support and wish them a healthy and prosperous 2018."
HUGE NEWS....
....and a signal to others wishing to get a piece to "GET IN LINE".....
Awesome
Wow what a day...!!
More TO COME....THIS IS JUST THE START....
NEWS !!!!
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2017) - Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) ("Pivot" or the "Company"), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), are pleased to announce that Pivot has signed a binding letter of intent to establish a California-based entity ("PGS-California") in order to accelerate the monetization of the Ready To Infuse Cannabis ("RTIC") technology as previously announced on December 20, 2017. Pivot plans to build manufacturing facilities in legal cannabis markets throughout North America and Europe, obtain the necessary licensures, and launch products using RTIC technology which transforms cannabis oil into powder for infusion. The letter of intent is subject to customary conditions including regulatory approval, the negotiation of a definitive agreement and satisfactory completion of due diligence.
Pivot seeks to gain market share in the food and beverage segment of the cannabis industry in legal markets in the near term through in-house brand development and by providing co-packing services for other edible brands through strategic partnerships. Co-packing services are an underserved, high-demand segment of the cannabis industry on the B2B side and will help further the awareness and visibility of the "Made with Instant THC" & "Made with Instant CBD" brands.
Pivot will appoint Ross Franklin and Patrick Rolfes to executive leadership roles within PGS-California to help execute its business strategy of conducting research, development and commercialization of cannabinoid-based products. Mr. Rolfes states that, "Pat and I look forward to working with Pivot to monetize the RTIC patents. Our facilities will be able to produce a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottle beverages."
Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals stated that, "Pivot continues to execute on its business strategy to upscale cannabis oils into premium healthcare and nutritional products. The California cannabis market is estimated to be worth $7B annually making it an attractive territory for Pivot's pipeline of products and technologies. We are also delighted to announce that Ross Franklin will join our Scientific Advisory Board. His extensive cannabis product development and commercial expertise will be a great asset to Pivot as we enter the US market."
Following the passing of Adult Use of Marijuana Act (Prop. 64), cannabis will be legal in California beginning January 1, 2018. California's main regulatory agencies are the Bureau of Cannabis Control (BCC), Department of Food and Agriculture, Department of Public Health and Cannabis Regulatory Authority (CRA). PGS-California will apply for all necessary licenses with the appropriate agencies.
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS' initial product development candidates will include topical treatments for women's sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com.
I think you are going to do very well here...